Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets

Vaccine

Volumn 32, Issue 25, 2014, Pages 3004-3009

  Onishi, Motoyasu ^a,b,c   Kitano, Mitsutaka ^a   Taniguchi, Keiichi ^a   Homma, Tomoyuki ^a   Kobayashi, Masanori ^a   Sato, Akihiko ^a   Coban, Cevayir ^c   Ishii, Ken J ^b,c  

^a SHIONOGI AND CO LTD   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Adjuvant; Ferret; Fluad; Influenza; Seasonal trivalent HA split vaccine; Vaccine

Indexed keywords

HEMAGGLUTININ; HEMOZOIN; INFLUENZA VACCINE; PYROGEN; SPLIT VACCINE; SYNTHETIC HEMOZOIN; UNCLASSIFIED DRUG; VACCINE; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FERRET; FEVER; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; INFLUENZA B; INFLUENZA VACCINATION; NONHUMAN; NOSE CAVITY; PRIORITY JOURNAL;

ADJUVANT; FERRET; FLUAD; INFLUENZA; SEASONAL TRIVALENT HA SPLIT VACCINE; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BODY TEMPERATURE; FEMALE; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMEPROTEINS; INFLUENZA B VIRUS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84899911460     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.072     Document Type: Article

References (28)

1. Sullivan D.J. Theories on malarial pigment formation and quinoline action. Int J Parasitol 2002, 32(13):1645-1653.
2. Arese P., Schwarzer E. Malarial pigment (haemozoin): a very active 'inert' substance. Ann Trop Med Parasitol 1997, 91(5):501-516.
3. Coban C., Ishii K.J., Kawai T., Hemmi H., Sato S., Uematsu S., et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005, 201(1):19-25.
4. Coban C., Igari Y., Yagi M., Reimer T., Koyama S., Aoshi T., et al. Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 2010, 7(1):50-61.
5. Tougan T., Aoshi T., Coban C., Katakai Y., Kai C., Yasutomi Y., et al. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models. Hum Vaccines Immunother 2013, 9(2):283-290.
6. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(1):1-15.
7. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(8):1159-1169.
8. Tetsutani K., Ishii K.J. Adjuvants in influenza vaccines. Vaccine 2012, 30(52):7658-7661.
9. Batista-Duharte A., Lindblad E.B., Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett 2011, 203(2):97-105.
10. Sauder D.N., Smith M.H., Senta-McMillian T., Soria I., Meng T.C. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 2003, 47(12):3846-3852.
11. Tanimoto T., Nakatsu R., Fuke I., Ishikawa T., Ishibashi M., Yamanishi K., et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 2005, 23(37):4598-4609.
12. Coban C., Yagi M., Ohata K., Igari Y., Tsukui T., Horii T., et al. The malarial metabolite hemozoin and its potential use as a vaccine adjuvant. Allergol Int 2010, 59(2):115-124.
13. Puig Barbera J., Gonzalez Vidal D. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. Expert Rev Vaccines 2007, 6(5):659-665.
14. Kitano M., Itoh Y., Kodama M., Ishigaki H., Nakayama M., Ishida H., et al. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother 2011, 55(11):4961-4970.
15. Kuroda E., Ishii K.J., Uematsu S., Ohata K., Coban C., Akira S., et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011, 34(4):514-526.
16. Della Cioppa G., Nicolay U., Lindert K., Leroux-Roels G., Clement F., Castellino F., et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults. Hum Vaccines Immunother 2012, 8(2):216-227.
17. Kitano M., Homma T., Taniguchi K., Oonishi M., Kobayashi M., Sato A., et al. Pyrogenicity evaluation of influenza vaccine with TLR agonists in ferret. Sixth Vaccine & ISV Annual Global Congress 2012.
18. Pickering J.M., Smith H., Sweet C. Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins. J Gen Virol 1992, 73(Pt 6):1345-1354.
19. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363(21):2036-2044.
20. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007, 25(44):7656-7663.
21. Matsuoka Y., Lamirande E.W., Subbarao K. The ferret model for influenza. Curr Protoc Microbiol 2009, 2. (Chapter 15:Unit 15G).
22. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25(19):3752-3762.
23. Treanor J.J., Taylor D.N., Tussey L., Hay C., Nolan C., Fitzgerald T., et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010, 28(52):8268-8274.
24. Shio M.T., Eisenbarth S.C., Savaria M., Vinet A.F., Bellemare M.J., Harder K.W., et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 2009, 5(8):e1000559.
25. Dostert C., Guarda G., Romero J.F., Menu P., Gross O., Tardivel A., et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009, 4(8):e6510.
26. Smirnov D., Schmidt J.J., Capecchi J.T., Wightman P.D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 2011, 29(33):5434-5442.
27. Kuroda E., Coban C., Ishii K. Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol 2013, 32(2):209-220.
28. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006, 40(1):1-9.